Interim analysis of the multicenter phase II HEDON trial evaluating pathological response to pre-operative docetaxel and docetaxel+trastuzumab (T) in locally advanced breast cancer (BR) stratified by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback